NCI Precision Medicine Study Hones in on Cancer Remission
Researchers say a non-chemotherapy treatment is causing more cancer patients to experience full remission.
A recent National Cancer Institute study shows that a new targeted therapy can help prolong the time cancer patients are in remission. Called the ViPOR regimen, the non-chemotherapy treatment shrinks tumors of those who suffer from B-cell lymphoma.
Dr. Christopher Melani, associate research physician with the Lymphoid Malignancies Branch in the Center for Cancer Research at NCI, highlights the importance of combining five therapies and administering them during a fixed cycle to maximize drug synergy and make tumors disappear.
He also shares details about the second phase of the study that is expected to take place later this year as well as how precision medicine could potentially lead to a cure for all types of cancer.
-
Dr. Christopher Melani Associate Research Physician, Lymphoid Malignancies Branch, Center for Cancer Research NCI
-
How AI Will Continue to Advance Biometric Tech
At Identity Week, Arun Vemury discussed how error rates in facial recognition have dropped over the past decade thanks to machine learning.
12m listen -
TSA is Innovating Digital Identity Solutions with AI
At Identity Week, Jason Lim talked about the ways that digital identity is changing the way people travel securely.
10m listen -
The Security and UX Standards That Power Digital Identity Programs
Live from Identity Week, Ryan Galluzzo discusses the latest draft of NIST's Digital Identity Guidelines for the identity-proofing process.
18m listen -
VA Delivers Record-Breaking Care Amid Surging Demand
Agency officials Dr. Shereef Elnahal and Joshua Jacobs said additional funding would sustain increased services to veterans.
4m read